Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) is a targeted radioligand therapy approved for treating prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). It is indicated for patients who have previously received androgen receptor pathway inhibitor (ARPI) therapy and are either considered appropriate to delay taxane-based chemotherapy or have already undergone such chemotherapy .

Pluvicto works by binding to PSMA-expressing cancer cells and delivering beta radiation directly to them, thereby damaging the tumor cells while sparing most healthy tissue . The treatment regimen consists of intravenous infusions every six weeks, for up to six doses . Common side effects include fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation .

This therapy is selected based on PSMA expression, confirmed through a specialized PET scan. Pluvicto represents a significant advancement in managing advanced prostate cancer, offering a targeted approach for patients with limited treatment options .